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Abstract 
Cathepsin B is a cysteine protease which has been implicated in the development and 
progression of various cancers. It is often redistributed to the plasma membrane, and inactive 
forms of the enzyme are commonly found in tumour tissue exudates. The secretion of 
cathepsin B from cancer cells is thought to correlate with their invasive potential. The 
purpose of this study was to identify and characterise polymorphism in the human cathepsin 
B gene. 
PCR was used in the amplification of ex on 7 and intron 7 of the human cathepsin B gene, 
using primers designed from the reported bovine and human cathepsin B genes. The t}VO 
resulting amplimers were of different size, revealing a potential polymorphism. 
10 human volunteers were screened for this variation, and sequencing of the variant 
amplimers identified two previously unreported alleles of the human cathepsin B gene. One 
allele is thought to confer increased stability to the primary transcript for cathepsin B, and 
hence may alter gene expression in homozygous carriers. 
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CHAPTERl 
Introduction 
1.1 Cathepsins 
Cathepsins are members of a large family of papain-type cysteine proteases, which also includes 
the calcium dependent calpains. Unlike the cytosolic calpains, the cathepsins are located in cell 
lysosomes, where they are predominantly found in active form. Cathepsins B, H, L, and S are all 
closely related through active site sequence homology and are similar in size, with the mature 
forms ranging from 24-32 kDa (Chapman et al., 1994). While they share high active site 
homology, the overall amino acid homology among the cathepsins is much less striking (20-
60% ). The two closest cathepsins in terms of sequence similarity are cathepsins L and S, which 
share 60% homology (Chapman et al., 1994). Table 1.1 illustrates conserved active site amino 
acid sequences between papain and the cathepsins. 
Table 1.1 Active site region amino acid homologies 
among papainatype cysteine proteases (from Chapman et al., 1994). 
19 * 170 
Papain -NQGSCGSCWAFS---YILIKNSWG 
19 * 179 
Cathepsin S -YQGSCGACWAFS---YWLVKNSWG 
19 * 182 
Cathepsin L -NQGQCGSCWAFS---YWLVANSWN 
23 * 214 
Cathepsin B --DQGSCGSCWAFG---YWLVANSWN 
2 0 * 182 
Cathepsin H -NQGACGSCWTFS---YWLVKNSWG 
* denotes the active site cysteine residue 
The cathepsin precursors all haveN-linked oligosaccharides containing mannose- 6-phosphate, 
which is typical of proteins that accumulate in lysosomes (Moin et al., 1992; Chapman et al., 
1994; Mach et at., 1994a). The lysosomal cathepsins are accepted as the proteases which 
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degrade defective or damaged proteins within the lysosome, and mediate the recycling of amino 
acids for new protein synthesis (Moin et al., 1992; Mordier et al., 1995). They are optimally 
active at acidic pH especially human cathepsin B, which suffers irreversible loss in activity and 
changes to secondary structure when exposed to pH 2 7.0 (Turk et al., 1994). Therefore the 
containment of cathepsins within the cell lysosome can be regarded as a protective mechanism. 
Any cathepsin activity accidentally rel~ased into the cell cytosol will not indiscriminately digest 
protein substrates, but is inactivated by the higher pH in the cell cytosol. 
1.2 Properties of cathepsin B 
Cathepsin B is the only cathepsin to possess C-terminal dipeptidase (en do- and exopeptidase) 
activity (Chapman et al., 1994; Zongchao et al., 1995). The mature protein exists in two forms: 
a single chain form of -30 k:Da (254 residues) and a double chain form with a heavy 25 k:Da 
chain and a lighter 5 k:Da chain (Mordier et al., 1995). The double chain form is produced by 
enzymatic cleavage between residues 47 and 50, with the loss of a dipeptide (Moin et al., 1992; 
Mordier et al., 1995). Human cathepsin B contains six disulphide bridges, one of which links the 
heavy and light chains (Mordier et al., 1995). 
Like other cathepsins, cathepsin B is synthesised as a latent precursor, or preproenzyme w6ich 
is subsequently converted to its mature form by limited proteolysis. All mammalian species 
produce a preproenzyme containing a 17 -residue prepeptide, a 62-residue proregion, a 253-
residue mature proteinase (254 in bovine), and a C-terminal extension of 6 residues for rat, 
mouse and human, and three residues in bovine cathepsin B (Mordier et al., 1995). Procathepsin 
B is cotranslationally glycosylated at Asn 113 (numbered according to the mature enzyme), and· 
possibly at Asn 42 in the proregion. A third potential site is found in human cathepsin B at Asn 
120. Phosphorylation of mannose residues in cis-Golgi allows for the specific binding of 
procathepsin B by mannose 6-phosphate receptors in the trans-Golgi network, to ensure accurate 
sorting to prelysosomal compartments (Mordier et al., 1995). 
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Activated cathepsin B is predominantly found in lysosomes, and it was originally assumed that 
this was the site of activation. Activated forms of cathepsin B have been found elsewhere within 
cells (endosomal compartments) suggesting that processing may occur earlier in the biosynthetic 
pathway, and is not strictly limited to the lysosome. It is now thought that the proteolytic 
processing of cathepsin B is initiated in prelysosomal compartments, and involves the cleavage 
of the propeptide, and the C-terminal extension. Excision of the dipeptide (residues 48 and 49) 
may occur in the lysosome through the action of other resident proteases. Removal of the 
dipeptide within the lysosome may decrease the stability of the active protein in alkaline 
conditions, and ensure that any activity lost to the cell cytosol is quickly inactivated. Mach et al., 
( 1994a) have reported that recombinant procathepsin B can be activated in vitro by a 
unimolecular autocatalytic mechanism, and that processing of the activated procathepsin to the 
mature form is a result of intramolecular processing. It is unknown as to what extent the 
proenzyme undergoes self activation and processing to the mature form in vivo. 
1.3 Cathepsin B and cancer 
The expression, post translational processing, and targeting of cathepsin B are all frequently 
altered in transformed and malignant cells (Gong et al., 1993; Calkins and Sloane, 1995; Mordier 
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et al., 1995). Increased expression or activity of cathepsin B has been observed in a variety of 
both human and murine tumours, specifically at the invasive edges of human prostrate carcinoma 
(Cao et al., 1994). Altered forms of cathepsin B (differing in size and stability) have been found 
in a variety of animal tumour cells and tissue culture exudates, including fluids from human 
breast and ovarian cancers. The elevated levels and variation in both form and proteolytic 
potency of this enzyme has led to its implication as a potentiator of tumour invasiveness and 
metastasis (Moin et al., 1992; Gong et at., 1993). 
The peripheral distribution of cathepsin B protein and activity explains the cosedimentation of 
cathepsin B with plasma membrane/endosomal fractions of malignant human and murine cells 
(Moin et al., 1992). Therefore levels of membrane associated cathepsin B may indicate tpe 
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metastatic or invasive potential of these tumours, due to its altered distribution and its ability to 
degrade extracellular matrix and basement membrane proteins (Turk et al., 1995). The 
transfection of MCF-1 0 human breast epithelial cells with oncogene ras leads to the association 
of cathepsin B containing lysosomes with the cell membrane (Sloane et al., 1994). The ability of 
oncogene ras to affect intracellular trafficking of cathepsin B is intriguing, as the re-distribution 
of lysosomes from around the nucleus t.o the cell periphery is a phenomena usually reserved for 
cells involved in degradative or invasive processes. 
Although cathepsin B is irreversibly inactivated in alkaline pH (Turk et al., 1994), active, high 
molecular mass forms have been reported in cultured tumour tissue exudates. Mach et al., 
( 1994b) observed the transient formation of a complex between the mature enzyme and its 
propeptide during autocatalytic proteolytic maturation of recombinant procathepsin B. They 
suggest that this complex occurs in vivo, and accounts for the high molecular mass forms present 
in tumour tissue exudates. Extracellular high molecular mass forms of cathepsin B may serve as 
latent enzyme pools, and dissociation of the complex followed by degradation of the inhibitory 
propeptide may occur in the acidic micro-environment surrounding living cells, i.e. in the 
extracellular matrix. The mature enzyme may then act on potential protein substrates until it 
becomes inactivated by the secretion of cysteine protease inhibitors, or by the neutral pH 
commonly encountered in body fluids (Mach et al., 1994b). 
Elevated cathepsin B gene expression is manifest through increased levels of mRNA and 
protein, during the early development of colorectal cancer (Murnane et al., 1991; Shuja et al., 
1991 ). Levels of cathepsin B activity in tumours associated with regional lymph-node 
metastasis, distant metastasis, and in normal tissues are significantly lower than levels in tumours 
which are confined to, or are invading the bowel wall. Therefore increased cathepsin B gene 
expression is a characteristic of tumours actively invading the bowel wall or local tissues 
(Murnane et al., 1991 ), and a decrease in gene expression seems to occur as the disease 
progresses. mRNA transcripts of different size (2.2, 4.0, 1.5 and 3.0 kb) are also evident, and 
may reflect alternative splicing of the primary transcripts. 
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Increased levels of cathepsin B activity in serum, and in tumour tissue are emerging as a 
prognostic factor in cervical carcinoma. Makarewicz et al., ( 1995) measured cathepsin B activity 
levels in 106 patients with cervical carcinoma, to estimate the usefulness of cathepsin B activities 
in determining the extent of the disease. They observed a positive correlation between serum 
cathepsin B levels and levels of cathepsin B in tumour tissue. In contrast to colorectal cancer, 
increased levels of tumour cathepsin B ~ctivity correlated with tumour metastases to pelvic 
lymph nodes in patients. Makarewicz et al., (1995) concluded that levels of cathepsin B activity 
may be useful in predicting the extent of cervical carcinoma in clinical practice. 
1.4 Cysteine protease inhibitors and cancer 
Cysteine protease inhibitors (CPis) are pseudoirreversible inhibitors with a high affinity for 
cathepsins (Calkins & Sloane, 1995). They contain a highly conserved amino acid sequence-
QVV AG-, which is partly responsible for their tight binding. Endogenous CPis constitute a 
single protein superfamily called the cystatins, which can be divided into four families: stefins 
(family I), cystatins (family II), kininogens (family III), and some non-inhibitory proteins (family 
IV). 
The cystatins are proposed to bind with cysteine proteases in areas adjacent to the active site, 
and exert their inhibitory effects by physically blocking the active site. There is no specific 
interaction with the cysteine, or any another residues within the active site. Figure 1.1 illustrates 
how stefin B may interact with cathepsin B. 
Stefin B is a more potent inhibitor of cathepsins LandS, and Figure 1.1 suggests that an 
equilibrium exists between stefin B and cathepsin B. The region of stefin B which occupies or 
blocks the active site is referred to as the "trunk". 
Active site Y ofcathepsinB 
~StefinB 
Figure 1.1 Interaction between cathepsin B and stefin B. "*"represents the region containing the-
QVVAG- consensus sequence (adapted from Calkins & Sloane, 1995). 
The progression of malignant tumours may be due in part to an imbalance in the CPI : cysteine 
protease ratio. A decrease in CPI activity or concentration may contribute to this imbalance. 
Two out of three breast carcinomas are reported to contain low CPI activity in comparison to 
normal breast tissue (Calkins and Sloane, 1995). As a result, breast cancer tissues possess 
increased cathepsin Band L activity which is probably due to reduced CPI activity. The 
remaining third of breast carcinomas have CPI activity equal to or higher than normal breast 
tissue. Stefin A in particular has come under scrutiny, as 4 out of 5 breast carcinomas have 
decreased levels of stefin A mRNA transcript (Lah et al., 1992; cited in Calkins and Sloane, 
1995). Reductions in stefin A protein levels parallel the decrease in CPI activity and stefin A 
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mRNA, suggesting stefin A is a major contributor to the observed CPI activity in breast tissue 
(Calkins & Sloane, 1995). Future study in this area will elucidate the involvement of cystatins in 
tumour progression. 
1.5 The human cathepsin B gene 
There is increasing evidence for the existance of one gene for human cathepsin B, despite the 
presence and generation of multiple mRNAs in both normal and transformed tissue. The 
cathepsin B gene had previously been mapped to two locations: 8p22 and 13q14, but has since 
been assigned to chromosome 8 at 8p22-p23.1 (Fong et al., 1992). The gene is large (in excess 
of 18 kb ), and contains 12 exons (Fig 1.2). Parts of exons 3 and 11, and the intervening exons 
( 4-1 0) are translated, and constitute preprocathepsin B. 
5' 
lkbp 
,____. 
El 
n 
E2 
n ? 
E3E4 [] I E5 I E6 E7 E9 I II I 
E8 
ElO Ell E12 
I DCJ 3, 
Figure 1.2 Structural organisation of the human cathepsin B gene. Solid areas are regions that encode 
preprocathepsin B. The sequence is deduced from two clones which contained discontinuous segments 
of the human cathepsin B gene, and"?" represents the unknown length of intron between exons E2 and 
E3 (adapted from Gong eta!., 1993). 
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In mammals, the cathepsin B gene exhibits a complete conservation of the intron exon junctions 
in the coding portion of its gene. The size and sequence of introns diverge between species 
(Mordier et al., 1995). Human cathepsin B is encoded by exons 3-11 (Gong et al., 1993), and 
Table 1.2 shows the nucleotides at the intron-exon boundaries, and the size of introns in the 
human cathepsin B gene. 
1.6 Evidence for alternative splicing of cathepsin B transcripts 
Different forms of cathepsin B and multiple mRNA types for this enzyme are produced in both 
normal and human tumour tissues, and generated early speculation that more than one cathepsin 
B gene existed. For example both normal and cancerous colorectal mucosa contain 2.2 and 4.0 
kb mRNA transcripts for human cathepsin B, whereas human osteoclastomas can contain 2.4, 
1.9, and 1.2 kb cathepsin B related mRNAs. Gong et al., (1993) isolated and characterised 
eDNA and genomic clones encoding cathepsin B from several human tissues and tumours. 
Human kidney and HepG2 (hepatocyte) cells were found to contain at least four different types 
of mRNA for cathepsin B, and a fifth type of transcript was present in only some human 
tumours. The preprocathepsin B coding sequence in all of the five different transcripts was 
identical, suggesting that the different mRNAs were derived by alternative splicing of mRNA 
derived from a single cathepsin B gene (Gong et al., 1993). 
Table 1.2 Nucleotides at the intron exon boundaries of the human cathepsin B gene (from Gong et al., 
(1993)). 
Ex on Exon size (bp) 5' splice donor lntron size (bp) 3' splice acceptor 
5' UTA 5' UTA 
1 124 CGCTGGgtgag ... -3500 ... tcccagGCTGGT 
5' UTA 5' UTA 
2 88 CGAGTAgtaag ... >5000 ... ctccagGTGGAT 
TrpGin AlaGiy 
3 151 TGGCAGgtagg ... 820 ... ttccagGCCGGG 
GlnArg Val Met 
4 86 CCAGACgtgag ... 1450 ... atccagAGTT ATG 
CysTrp AlaPhe 
5 i iS TGCTGGgttaag ... 1750 ... ctgcagGCCTTC 
AspGiy CysAsn 
6 119 GGACGGgtaag ... 750 . .. tttcagCTGTAA T 
His Val GlyCys 
7 86 CATGTAGgtaag ... 230 ... catcagGGTGCA 
HisTyr GlyTyr 
8 144 CACTACGgtaag ... 470 ... ttccagGAT ACA 
LysSer GlyVal 
9 117 AAGTCAGgtgcg ... 1380 ...tttcagGAGTGT 
AspAsn GlyPhe 
10 129 GACAATGgtgag ... 470 . .. tcccagGCTTCT 
3'UTA 3' UTA 
11 142 ATCGGGgtaga ... 823 .. .ctgcagAGAA TC 
J2 2700 
The five different transcripts characterised by Gong et al., (1993) are illustrated in Figure 1.3. 
Type l is the largest transcript produced, and contains a 237 nucleotide 5' untranslated region 
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(UTR), 1017 nucleotides which encode preprocathepsin B, and a 2800 nucleotide 3' UTR. Types 
1 and 2 ( 4 kb in length) differ from each other through the deletion of 88 nucleotides in the 5' 
UTR in type 2. Types 3 and 4 (2.3 kb in length) differ from each through the same deletion of 88 
nucleotides in the 5'UTR in type 4. 
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lm=Typel 
lm= 2 
B Poly A 3 
Poly A 
B 5 
Figure 1.3 Cathepsin B transcripts in human tissues. Overlapping eDNA clones corresponding to 
mRNA types 1, 2, 3, and 4 were isolated from human kidney and HepG2 phage libraries. The type 5 
transcript was characterised by PCR, and the 3' untranslated region associated with this transcript has not 
been determined. Solid black boxes indicate the 88 nucleotide sequence contained in mRNA types 1 and 
2, but deleted in mRNA types 2, 4, & 5. The type 5 transcript also has an additional 155 nucleotide 
deletion corresponding to the signal peptide (S), and 7 amino acid residues of the propeptide (P). Cross 
hatched boxes indicate the alternative 3'- UTRs (adapted from Gong et al., 1993). 
Processing at a cryptic intron donor site in exon 11 and splicing to exon 12 produces the larger 
type 1 and 2 mRNAs, with alternate 3' UTRs. mRNAs with the 88 nucleotide deletion in thyir 5' 
UTRs are produced as a result of the variable removal of exon 2 (types 2, 4 and 5). 
Gong et al., (1993) observed that the ratio of 4.0 kb to 2.3 kb mRNA transcripts in most tissues 
examined was 2:1, but the ratio of 5' UTR variants differed widely. In particular, mRNAs 
lacking exon 2 were most predominant in human tumours. Human melanoma, breast and colon 
carcinomas all contained the type 5 transcript which lacks exons 2 and 3 which code for the 
signal peptide and 7 amino acids of the activation propeptide. 
An in vitro transcription/translation assay was performed by Gong et al., (1993), and 
demonstrated that the different mRNAs had different rates of translation. The relative rates of 
translation for the type 5 transcript, types 2 and 4, and types 1 and 3 were 8:2: 1, and indicate that 
the smallest type 5 transcript can be translated in vitro, and quite quickly in comparison to 
mRNAs which contain the full5' UTR (types 1 and 3). Gong et al., (1993) concluded that the 
expression of cathepsin B in human tissues may be regulated in part at the level of mRNA 
processing. 
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In vitro translation of the type 5 transcript is thought to start from an in-frame methionine 
residue (52) within the propeptide region. The resulting 32 kDa product lacks the signal peptide 
and the first 34 residues of the 62 amino acid propeptide region. It is no longer targetable to the 
lysosome, and could explain why some tumour tissues show a redistribution of cathepsin B to the 
plasma membrane, secretory vesicles, and to the cell nucleus. Tumour cells are known to secrete 
higher molecular weight forms of cathepsin B, in latent and active forms. This could reflect 
alterations in the linked targeting and post-translational processing of cathepsin B that result in 
changes in the amount and composition of the oligosaccharide side chains, and the extent of 
proteolytic modifications. The findings of Gong et a/.,(1993) also imply that variable splicing of 
the cathepsin B mRNA transcript can also complement the diversity of cathepsin B form and 
function seen in both normal human and tumour tissues. Translation of the type 5 transcript in 
vivo has yet to be determined, but if translation occurs, then the protein product could be located 
in the cell cytosol and/or the nucleus. Its role could be in the modulation of cellular activity 
through the proteolytic modification of key regulatory proteins (Gong et al., 1993). 
1. 7 Polymorphisms in the cathepsin B gene 
There are few identified polymorphisms in the human cathepsin B gene. Those which have 
been published are usually identified through the use of complimentary DNA sequences. 
Variation in the 5' and 3' UTRs is often seen, but has little effect upon the size and shape of the 
protein produced. 
Cao et al., (1994) analysed full length human preprocathepsin B eDNA clones from gastric 
adenocarcinoma for sequence modifications potentially linked to the altered intracellular 
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trafficking and secretion of cathepsin B. A 10 bp insertion (CATCAGACCT) in the 3' UTR not 
found in the kidney and hepatoma cathepsin B cDNAs by Chan et al., ( 1986) was identified. 
Cao et al., (1994) concluded that the 10 bp insertion could potentially alter mRNA stability and 
hence alter cathepsin B gene expression. Tam et al., (1994) independently characterised the 
same 10 bp insertion in the 3' UTR of cathepsin B in lung fibroblasts. With reference to the 
results of Cao et al., ( 1994) Tam et al., ( 1994) postulated that the 10 bp insertion occurs naturally, 
and may have been deleted in the cDNAs studied by Chan et al., (1986). The 10 bp insertion can 
take part in the formation of a stable stem loop structure within the cathepsin B mRNA 
transcript, and may provide binding sites for regulatory proteins that can modify the stability of 
this message. If the 10 bp insertion was deleted, then the kidney and hepatoma cathepsin B 
mRNAs characterised by Chan et al., (1986) may have had altered stability in comparison to 
transcripts from fibroblasts, or from the human gastric adenocarcinoma. 
In addition to the 10 bp insertion, Cao et al., (1994) also reported the following variations in the 
human cathepsin B gene, which were identified using four eDNA clones isolated from a human 
gastric adenocarcinoma eDNA library: 
e a nucleotide substitution in the coding region for the propeptide from GTG to CTG, 
resulting in a Val26¢ Leu change. 
e three silent nucleotides replacements in the coding region for the mature protein. 
e five single nucleotide substitutions.in the 3' and 5' untranslated regions. 
e heterogeneity in the 5' untranslated region. 
e two restriction fragment length polymorphisms Eco RI and Taq I. 
1.8 Objectives 
The objectives of this study were to identify any polymorphism(s) in the human cathepsin B 
gene using PCR technology, and to characterise any polymorphism(s) found. 
CHAPTER2 
Amplification of the human cathepsin B gene. 
2.1 Introduction 
The Polymerase Chain Reaction (PCR! was developed in 1985, and enables users to amplify 
specific gene sequences from a complex mixture of genomic material (PCR Protocols, 1990). 
After amplification the amplimers can be visualised as bands on agarose gels. 
The polymerase chain reaction was used in this study to amplify what would potentially be 
342 nucleotides of the human cathepsin B gene, including intron 7. This would be 
accomplished using primers that shared 100% homology with human cathepsin B gene 
sequence published by Chan et al., (1986). 
2.1.1 Selection of primers and development of initial PCR reaction 
The selection of adequate primers is a critical step in the development of a PCR method. In 
a previous study (Markham, 1994), two primers were designed to amplify a region of the 
ovine cathepsin B gene. They were: Bocthex8 (5'-GGGAGGGATGGAGTACGGTCTGCA-
3'), and BovcthU (5'-GAGTGGCTCTTTTCTCCAGCTGTAACGG3). Bocthex8 is located in 
ex on 8 of the human cathepsin B gene, and also shares 100% homology with bovine 
cathepsin B sequence (Appendix A.l). The BovcthV primer was originally used by Mordier 
et al., (1993) to study polymorphism in the bovine cathepsin B gene. 
In this study, Bocthex8 and BovcthU were used to try and amplify human cathepsin B. No 
amplification of any part of the human genome was observed (results not shown). 
Gong et al., (1993) reported the nucleotides surrounding the intron-exon boundaries for 
human cathepsin B, and also reported the size of each intron and exon (Table 1.2 pp 8). 
Several introns were sufficiently small enough to be used as potential candidates for PCR 
amplification. The previously used primer Bocthex8 was complementary to the start of exon 
8 (Fig 2.1) of the human cathepsin B gene sequence first published by Chan et al., (1986). 
Due to the availability of a suitable primer in exon 8 and the small size of intron 7 (230 bp), a 
region spanning intron 7 was chosen for amplification using a new primer located upstream 
in ex on 7. The computer Oligo ™ computer program was used to identify a suitable primer in 
the 5' end of exon 7 which formed limited primer-dimer with itself and Bocthex8, and 
limited stable secondary structure such as loops, which can interfere with the PCR reaction. 
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This primer (named "HucathU"), is shown in Figure 2.1. When used in conjunction with 
Bocthex8, the 342 bp amplimer was anticipated to contain most of exon 7 (85 of 86 bp), all 
of intron 7 (230 bp ), and the first 27 bp of ex on 8. 
HucathU 
Exon 7 
TGTAATGGTGGCTATCCTGCTGAAG 
CTGTAATGGTGGCTATCCTGCTGAAGCTTGGAACTTCTGGACAAGAAAAGGCCT 
GGTTTCTGGTGGCCTCTATGAATCCCATGTA 
------------ ----~---intron7 ---
Bocthex8 ACGTCTGGCATGAGGTAGGGAGGG 
Exon 8 GGGTGCAGACCGTACTCCATCCCTCCCTGTGAGCACCACGTCAACGGCTCCCGG 
CCCCCATGCACGGGGGAGGGAGATACCCCCAAGTGTAGCAAGATCTGTGAGCCT 
GGCTACAGCCCGACCTACAAACAGGACAAGCACTACG 
Figure 2.1 Primer Alignment with Human Cathepsin B Gene Sequence (Gong et al., 1993; Chan et 
al., 1986). 
G + C content was 62.5% for Bocthex8, and 48% for HucathU. The melting temperature 
(T m) was calculated for each primer using the methods of Thein & Wallace ( 1986), giving T m 
:::: 78°C for Bocthex8 and T m:::: 74°C for HucathU. 
Homology of both HucathU and Bocthex8 primers with the human cathepsin B gene was 
confirmed using the NCBI Blast server (Blast@NCBI.NLM.NIH.GOV). The results of each 
search are in Appendix A.l. Synthesis of the Hucath U primer was performed by Canterbury 
Health Laboratories, Christchurch, New Zealand. 
2.1.2 Development of whole blood PCR protocol 
Ohhara et al., (1994) previously reported the successful amplification of a mouse retinoblas-
toma susceptibility gene from DNA in microwave-irradiated whole blood. It was concluded that 
microwave irradiation destroyed cell structures and exposed the genomic DNA, and that it also 
denatured proteins or proteases which could interfere with the PCR reaction. 
Experimentation with microwave-irradiated whole blood PCR was carried out. Subject 1 
volunteered 2 J.LL aliquots of whole blood (obtained with a lancet), which were placed in a PCR 
reaction tube and microwaved on high over a range of times from 1 - 4 minutes. The 
microwaved blood then had the following PCR reagents added on ice: 
10 x PCR reaction buffer (Boehringer Mannheim) 2.0 IlL 
Water (Appendix 2.A) 14.8/lL 
HucathU (50 mM) 0.4 IlL 
Bocthex8 (50 mM) 0.4 IlL 
dNTPs (0.25 mM) (Boehringer Mannheim) 0.2 IlL 
T AQ polymerase (50 U//lL) (Boehringer Mannheim) 0.2 ~L 
Total volume (including blood) 20.0 IlL 
A reagent blank containing PCR reagents and 21-LL of water instead of whole blood was in-
cluded during every PCR amplification, and all tubes were overlaid with mineral oil to inhibit 
evaporation. PCR amplification was carried in a COY™ Tempcycler II multicycler (COY 
Laboratory Products Inc.) using the following conditions recommended by Couldrey (1995). 
Tubes were subjected to an initial pre-denaturation step of 94°C for 3 minutes. This was 
followed by 35 cycles of denaturation at 94°C for 30 seconds, and annealing and primer 
extension at 60°C for 6 minutes. Tubes were stored at 4°C overnight if necessary. PCR 
products were viewed following gel electrophoresis. 
2.1.3 Agarose gel electrophoresis and visualisation of amplimers 
Agarose gel electrophoresis is a quick and simple way to determine both the size and quantity 
of PCR products, and can also be used to check primer specificity. If binding is non-specific 
(two or more bands of DNA are produced), then PCR reaction conditions may need to be 
modified. 
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PCR products (usually 5 IlL) were mixed with a small volume (l!lL) of load buffer (Appendix 
A.2), and loaded into sample wells of 2% agarose gels (Appendix A.2). They were then 
electrophoresed at 10 V cm-1 for 50 minutes, conditions which were sufficient to enable 
estimation of the size of PCR products. Bands of DNA were visualised on a UV transilluminator 
(Watson Victor UVP Gel Documentation System). 
This whole blood PCR protocol did not generate any observable product, except for a few faint 
bands when all 20 IlL of PCR reaction was loaded onto agarose gel (results not shown). The 
method was continually modified (results not shown) until reproducible results were achieved 
(see following section). 
2.1.4 Revised whole blood PCR 
Whole blood PCR was revised so that of 2 J..lL of whole blood (human subject 1) were mixed 
with 4 J..lL water and then microwaved. Mixing with water lysed blood cells, released genomic 
DNA into the extracellular milieu. PCR reagents were then added as follows: 
10 x PCR reaction buffer 
Water 
HucathU (50 mM) 
Bocthex8 (50 mM) 
dNTPs (0.25 mM) 
T AQ polymerase (50 U/f..lL) 
Total volume (including 6J.1L blood/water) 
2.0 J..lL 
10.8 J..lL 
0.4 J..lL 
0.4 J..lL 
0.2J..lL 
0.21J.L 
20.0J..lL 
This method generated two amplimers differing in size by about 20 bp (380 and 360 bp). 
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Varying the time period of microwave irradiation identified 2.5- 3 minutes as the ideal length of 
time for the diluted blood sample to be irradiated (Figure 2.2). 
394 bp 
Figure 2.2 Agarose Gel of Whole Blood PCR. Each lane was loaded with 20 f..!L of PCR product. 
Contents of each lane (left to right) were PCR reactions containing blood/water mixtures irradiated on 
high for; 2 minutes, 2 minutes 30 seconds, 2 minutes 45 seconds, and 3 minutes. Lanes 2 and 4 contain 
two distinct bands of DNA for subject 1. 5 )..lL of molecular weight marker VI (Appendix A.2) were 
loaded in lane 5. The 394 bp fragment in the molecular weight marker is labelled. 
2.1.5 Discussion 
This method of whole blood PCR differed from that of Ohharra et al., ( 1994 ), as it did not 
incorporate the use of Tris-HCI, added KCl, or Triton® X-100. Instead, water was used to 
lyse blood cells by osmotic pressure before microwave irradiation. Two bands of PCR 
product were produced during PCR amplification. 
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DNA from subject 4 was available (by consent) through previous work undertaken by Craigen 
(1995). This DNA was amplified concomitantly with whole blood PCR for comparison, and as a 
control. Reaction mixtures were prepared as in section 2.1.2 except that 2 J..lL of whole blood 
were substituted with 0.5 J..lL of DNA (199 ng/J..LL), and 16.3 J..lL water was added to each tube. 
DNA from subject 4 generated 2 bands of PCR product similar to whole blood PCR results for 
subject 1, and again was thought to result from non-specific primer binding (results not shown). 
Steps were then taken to optimise the PCR reaction so that only one amplimer was produced. 
The whole blood PCR method was abandoned in favour of using preparations of genomic DNA. 
Further investigation using primers for different genes and blood from different animals, may yet 
identify this novel method which incorporates water to lyse blood cells, as a quick and easy 
method for the generation of PCR products. 
2.2. Refinement of PCR methodology 
2.2.1 Introduction 
Non specific primer binding was suspected, because genomic DNA from subjects 1 and 4 
generated two amplimers. Attempts to increase binding specificity by raising the annealing~ 
temperature and performing a magnesium ion titration with DNA form subject 4 were 
undertaken. 
The magnesium ion titration was performed simultaneously with an increase in the 
annealing and extension temperature from 60°C to 64 °C. Raising the temperature to 64 °C 
meant that primer binding would be more specific, and performing a magnesium ion titration 
would identify the best ion concentration for optimal Taq polymerase activity. Magnesium 
ion concentration can also influence the specificity of primer binding. 
2~-LL of magnesium chloride solution (0.0, 0.5, 1.0, 1.5, 2.0, 2.5, or 3.0 mM) were added to 
tubes, and the following reagents added: 
DNA (199ng/~-LL) 
10 x Mg++ free PCR buffer (Boehringer Mannheim) 
Water 
HucathU (50 mM) 
Bocthex8 (50 mM) 
dNTPs (0.25 mM) 
T AQ polymerase (50 UI~-LL) 
Total volume (including magnesium chloride) 
2.2.2 Results 
0.5 IlL 
2.0 IlL 
16.3 IlL 
0.4~-LL 
0.4~-LL 
0.2~-LL 
0.2~L 
20.0 IlL 
Figure 2.3 illustrates that raising the annealing and extension temperature by 4°C did not alter 
primer specificity in any way, because two amplimers were still produced. No amplification 
was observed at 0.0, and 0.5 mM ion concentrations, but the two amplimers persisted over 
the range of ion concentrations from 1.0- 3.0 mM. 
Figure 2.3 PCR banding pattern for subject 4 over a range of magnesium ion concentrations. The 
ion concentrations (mM) for each reaction tube are listed along the top of the gel in white. 10 IlL of 
each reaction tube were loaded, and 5 IlL of molecular weight marker VI were loaded in lane 8. 
(Numbered left to right). 
The annealing and extension temperature was decreased to 60°C, and 2 IlL of 10 x PCR 
reaction buffer added to all subsequent PCR reactions so that magnesium ion concentrations 
in each tube were equal to 1.5mM. 
Genomic DNA extracted from human colo-rectal tumour tissue was provided by Dr. S. 
Damak for comparison. This DNA (lOOngi~-LL) was amplified along with that of subject 4, 
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and the water content in each PCR reaction was adjusted to accommodate the differences in 
DNA concentrations. Agarose gel electrophoresis of PCR products revealed that tumour 
tissue generated only one amplimer in comparison to the 2 bands for subject 4 (Figure 2.4). 
Figure 2.4 PCR banding patterns generated from DNA of human subject 4 and tumour tissue. 
Lanes 1 and 2 (numbering is from left to right) contained 5 and 15 ~-tL respectively of PCR product 
for subject 4. Lanes 4 and 5 contained 5 and 15 ~-tL of PCR product for human tumour tissue. 5 ~-tL 
of molecular weight marker VI were loaded in lane 3. 
2.2.3 Discussion 
DNA from subjects 1 and 4 generated two bands of PCR product, which were 
approximately 360 bp and 380 bp. Tumour tissue DNA generated only one PCR product 
(380 bp). The persistence of two amplimers at the increased annealing temperature over a 
range of magnesium ion concentrations and the presence of only one amplimer from tumour 
tissue DNA suggested that more than one allele existed for human cathepsin B. The primers 
(HucathU and Bocthex8) were perhaps binding both alleles in the heterozygotes (subjects 1 
and 4), and the individual from whom the tumour tissue DNA was sourced was possibly 
homozygous, generating the 380 bp amplimer only. 
Different alleles of human cathepsin B gene have not been identified to date, despite the 
generation of multiple mRNAs from a variety of both normal and transformed tissues (Gong 
et al. , 1993). Results from these experiments were not conclusive for the existence of two 
alleles, because one DNA sample had been sourced from (abnormal) tumour tissue. To 
address this issue there was a requirement for genomic DNA to be both sourced and extracted 
from the same tissue, using a uniform method. 
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CHAPTER3 
Preparation of 10 human genomic DNA samples for gene analysis 
3.1 Introduction 
DNA for gene analysis was extracted from human blood. The white blood cell fraction is a 
primary source of genomic DNA, and although blood-taking is an invasive technique, it is 
preferred over tissue removal. Approval for human blood to be collected for use in gene analyses 
was received from the Lincoln University Human Subjects Committee on the condition that 
volunteers completed the informed consent form in Appendix B .1. The 10 volunteers (subjects 1 
-1 0), were current blood donors and assumed to be free of known blood-bourne diseases. This 
distinction was made so that the handling of any blood products before, during, and. after DNA 
extraction was relatively risk free, although all safety precautions pertaining to the use of human 
biological samples were observed. A follow up of the ten volunteers did not indicate any trauma 
had arisen as a result of sampling. Human subjects 1 and 4 had participated in previous 
experiments for this study. 
3.2 Hi-Salt DNA extraction from whole blood 
The Hi-Salt DNA extraction protocol was obtained from Environmental Sciences and Research 
(ESR, Canterbury, New Zealand), and is specifically designed for the recovery of DNA from 
human blood. 
10 mL of blood was collected in vacutainer™ blood collection tubes containing EDT A. 200 IlL 
of each blood sample was used for DNA extraction, and the remainder was stored at -18°C. 800 
IlL of red and white blood cell lysing solution (Appendix B.2) was added to 200 IlL of blood in a 
1.5 mL eppendorf tube, and each tube gently inverted every five minutes at room temperature for 
30 minutes. Samples were then centrifuged at 13000 rpm for 2 minutes (Biofuge 13, Heraeus 
Sepetech GmbH). The supernatant was discarded and the pellet washed with 100 IlL aliquots of 
washing buffer (pH 8, Appendix B.2), with subsequent centrifugation (13000 rpm for 2 minutes), 
and repeated disposal of the supernatant. This washing step was repeated either 8 times or until 
the pellet was white. 400 IlL of soJubilisation solution (Appendix B.2) was added to the washed 
pellet and heated for 15 minutes at 100°C. The mixture was then neutralised with 100 IlL of pH-
8 neutralising buffer (Appendix B.2). Contents of the eppendorf tube were vortexed, centrifuged 
at 13000 rpm for 2 minutes, and the supernatant containing genomic DNA retained. The 
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concentration of DNA in each raw sample was then estimated and diluted with water if necessary 
(section 3.3). 
3.3 Estimation of raw genomic DNA concentrations 
A blank containing 4 J.LL of solubilisation buffer, 1 J.LL of neutralising buffer (pH 8), and 495 
J.LL of water, was placed in the referenc~ beam, and 5 J.LL of genomic DNA suspension diluted to 
500 J.LL with water (100 x dilution) was placed in the sample path of a double beamed scanning 
spectrophotometer (Perkin-Elmer). The absorbancies at wavelengths 200-300 nm were recorded. 
Equation 3.1 was used to calculate the concentration of DNA in the original sample: 
Equation 3.1. DNA concentration in Jlg/mL = A260 x 50 x dilution 
Scanning between these wavelengths also gave an indication of the purity of each sample. A 
strong peak at 260nm was indicative of a high DNA concentration, and a low peak shoulder at 
280nm (wavelength at which the peptide bond absorbs) indicated a sample low in protein. 
Figure 3.1 represents a scan of a pure DNA sample. 
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Figure 3.1 Scan of a pure DNA sample (From Couldrey, 1994). 
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For pure DNA the A26ofA280 ratio is 1.8, with values less than this indicating the presence of 
protein and values greater than 1.8 indicating contamination with RNA. Following estimation 
of concentration appropriate aliquots of each DNA sample were diluted with water to give a 
concentration of 100 ng/J.LL, then stored at 4 ° C. 
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3.4 Results and discussion 
Table 3.1 lists the DNA concentrations for subjects 1-10 (J.Lg/mL), the total amount of DNA 
extracted (J.Lg), and the purity of the samples (A26r/A280). The A26r/A280 ratios ranged from 1.01 
to 1.15, and indicate that the Hi-Salt method for DNA extraction may generate impure genomic 
DNA preparations. 
Table 3.1 Raw genomic DNA concentrations and purity 
!Subject I A260 IEJI = II Vo~~me II 
1 0.043 0.04 1.13 500 
2 0.173 0.17 1. 01 500 
3 0.110 0.10 1. 06 500 
0.051 0.05 1.11 500 
0.050 0.05 1.11 500 
6 0.046 0.04 1.15 500 
7 0.071 0.07 1. 09 500 
8 0.045 0.04 1.13 500 
9 0.049 0.04 1.11 500 
10 0.048 0.04 1.14 500 
Cone. 
ug/mL 
215.00 
865.00 
550.00 
255.00 
250.00 
230.00 
355.00 
225.00 
245.00 
240.00 
II D~gA I 
107.50 
432.50 
275.00 
127.50 
125.00 
115.00 
177.50 
112.50 
122.50 
120.00 
Unlike many other protocols for DNA extraction from mammalian blood samples the Hi-Salt 
DNA extraction method does not employ the use of a non-specific protease such as proteinase K, 
which may explain the high protein contamination. However the protocol is sufficient 
preparation of genomic DNA "clean" enough for PCR amplification, and it is not especiallytime-
consuming. 
CHAPTER4 
PCR amplification of genomic DNA from 10 individuals 
4.1 Introduction 
PCR was used to produce amplimers from genomic the DNA of 10 human subjects. The 
banding patterns for subjects 1 and 4 seen in earlier experiments were reproduced, and 
banding patterns similar to that for DNA extracted from tumour tissue were also observed. 
4.2 PCR reagents and reaction protocol 
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Preparation of 10 human DNA samples of the same concentration (100 ng/J.LL) allowed for PCR 
reactions to be made up to the following uniform method, which was used in all subsequent PCR 
reactions: 
DNA (100 ng/J.LL) 
10 x PCR reaction buffer 
Water 
HucathU (50 rnM) 
Bocthex8 (50 rnM) 
dNTPs (0.25 rnM) 
TAQ polymerase (50 U/J.LL) 
Total volume 
4.3 Results and discussion 
1.0 J.LL 
2.0 J.LL 
15.8 J.LL 
0.4 J.LL 
0.4 J.LL 
0.2 J.LL 
0.2~L 
20.0 J.LL 
Amplification of genomic DNA for subjects 1-10 revealed banding patterns strongly 
suggestive of two different alleles for human cathepsin B (Figure 4.2). 
To confirm that the different banding patterns were a result of different alleles, it was decided 
that the 360 and 380 bp amplimers should be sequenced. Sequencing the amplimers would 
confirm that they were produced by amplification of the human cathepsin B gene, and would also 
characterise the alleles. Subjects 8 and 10 were putative homozygous carriers of each allele, and 
their corresponding amplimers were chosen for sequencing. 
Figure 4.2 Banding patterns suggestive of two different alleles amongst ten human subjects. 10 f.lL 
of each PCR product were loaded, and 5 f.lL of 100 base pair ladder (Appendix A.2) were loaded in 
lane 11. The 300 and 400 bp fragments are indicated (numbering is from left to right). 
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CHAPTERS 
Preparation of purified amplimers for sequencing 
5.1 Introduction 
The isolation of PCR products free of any contamination such as protein, genomic DNA, salts, 
etc. is important, as these impurities can affect DNA sequencing. DNA sequencing required 
appreciable amounts of template DNA. Promega's Wizard™ PCR Preps DNA Purification 
System and Boehringer Mannheim's Agarose Gel DNA Extraction Kit were used to purify PCR 
products for sequencing. 
5.1.1 Wizard™ PCR preps DNA purification system (Promega). 
70 tubes of PCR product amplified from subject 8's genomic DNA produced 1.4 mL of pooled 
PCR product. 2% TAE agarose gels (2) were used to separate PCR product from any unused 
dNTPs etc. After electrophoresis the bands of DNA were cut out from each gel using a sterile 
scalpel blade, over a UV light source. The 2 excised bands of agarose were then solubilised in 3 
mL of purification resin* in a 15 mL Falcon™ tube at 65° C for 6 minutes. 2.0 mL aliquots of 
the solubilised resin/DNA suspension were poured onto 2 minicolumns using a 3 mL plastic 
syringe, and each column was then washed with 2 mL of 80% isopropanol. The 2 minicolumus 
were then placed in a 1.5 mL microcentrifuge tube and centrifuged at 12000 rpm for 20 seconds 
to dry the resin. They were then transferred to·a clean 1.5 mL microcentrifuge tube, and 50JlL of 
water was pipetted onto the top of each column. After one minute each minicolumn was 
centrifuged at 12000 rpm for 20 seconds to elute the purified DNA into the 1.5 mL mi-
crocentrifuge tube. 
PCR product amplified from DNA from subject 10 was purified in the same way. 
5.1.2 Agarose gel DNA extraction kit (Boehringer Mannheim). 
70 tubes ofPCR product amplified from subject 8's genomic DNA produced 1.4 mL of pooled 
PCR product. 2% TAE agarose gels (2) were used to separate PCR product from any unused 
*All reagents used in both methods (except water) were provided with the respective purification 
kits. 
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dNTPs etc. After electrophoresis the bands of DNA were cut out from each gel using a sterile 
scalpel blade, over a UV light source. The excised bands were combined with 12 mL of agarose 
solubilisation buffer in 15 mL Falcon tube. lOJ.LL of silica suspension were then added and the 
mixture incubated at 56°C for 10 minutes to melt the agarose. During incubation the tubes were 
vortexed once every 2-3 minutes. The mixture was then centrifuged in an ultracentrifuge 
(Beckman J2-Ml, USA) for 30 seconds at 13000 rpm and the supernatant discarded. The pellet 
(silica matrix and bound DNA) was resuspended in 500J.LL of nucleic acid binding buffer, and 
transferred to a 1.5 mL centrifuge tube .. This was centrifuged for 30 seconds at 13000 rpm 
(Biofuge 13, Heraeus Sepetech GmbH), and the supernatant discarded. The pellet was washed 
twice with 500J.LL of washing buffer with intermittent centrifugation at 13000 rpm for 30 
seconds, and the supernatant's discarded. The pellet was then dried over a paper towel at room 
temperature for 15 minutes, and resuspended in 50J.LL water (pH 8.5), by vortexing every 2-3 
minutes over a period of ten minutes. The resulting suspension was then centrifuged for 30 
seconds at 13000 rpm, and the supernatant containing purified PCR product kept. 
PCR product amplified from DNA from subject 10 was purified in the same way. 
5.1.3 Results and discussion 
Yields from the Wizard™ PCR prep kit were suspected to be low (results not shown). 
Recovery for this kit declines with fragment length, with typical yields of 70-90% for 500 bp 
fragments and 3% for 50 bp fragments. The smallest purified amplimer was - 360 bp, and th,e 
worst case scenario meant that product recovery was as low as 52%. The Agarose Gel DNA 
Extraction Kit (Boehringer Mannheim) was trialed as it should give an 80% recovery for a 
fragment of similar length (370 bp). 
Although it worked sufficiently, the Agarose Gel DNA Extraction Kit (Boehringer Mannheim) 
was not suited to the isolation of large amounts of DNA from agarose. The kit was used only 
once for the purification of each amplimer from corresponding subjects 8 and 10, before the 
provided agarose solubilisation buffer became limiting. 
Knowing the concentration of template DNA for sequencing was critical, as too much template 
DNA can inhibit the sequence reaction. The concentrations of each purified amplimer were 
measured by one of the two following methods: estimation by gel electrophoresis, and 
measurement of the absorbency at 260 nm. 
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5.2 Measurement of purified amplimer concentration by gel electrophoresis 
Molecular weight marker VI (Boehringer Mannheim) contains 15 fragments: 154, 154, 220, 
234,234,298,298,394,453, 517,653, 1033, 1230, 1766, and 2176 bp, and the sum of all the 
base pairs (154 + 154 + 220 ....... + 2176), is 9814 bp. The amount of DNA for any one fragment 
can be calculated if the dilution factor for the molecular weight marker is known. For instance, 
10 J.LL of the diluted molecular weight marker VI (Appendix A.2) contains a total125 ng of 
DNA, and equation 5.1 gives the amount of DNA for the 394 bp fragment. 
Equation 5.1 394/9814 x 125 ng = 5.0 ng of DNA 
The 394 bp fragment is similar in size to the purified amplimers, and when purified amplimers 
were electrophoresed alongside 10 JlL of molecular weight marker VI, their concentrations could 
be estimated according to band intensities. Choosing a fragment of similar size was important 
because DNA binds ethidium bromide semi-quantitatively, and a different fragment would have 
given misleading results. 
1 J.LL of load buffer was mixed with 1 J.LL of purified amplimer and loaded onto a 2% agarose 
gel alongside a lO!!L of molecular weight marker VI. After gel electrophoresis the intensity of 
the band for each purified amplimer was compared to the intensity of the 394 bp fragment, and a 
simple back-calculation (equation 5.2) gave the DNA concentration for each purified amplimer. 
Equation 5.2 Intensity factor x 5 = [DNA] of purified amplimer (ng/J.LL) 
5.2.1 Results and discussion 
Figure 5.1 illustrates a gel loaded with purified amplimer for subjects 8 and 10. Band 
intensities were best estimated when the gel was still on the UV transilluminator, rather than 
from a photograph. 
The Wizard™ PCR preps kit produced 100 J.LL of purified amplimer from 70 PCR tubes. 1 J.LL 
of each purified amplimer produced bands 6 times as intense as the 394 bp fragment of the 
molecular weight marker. Therefore the estimated DNA concentration for each purified was 30 · 
ng/J.LL. 80 IlL of each purified amplimer were then concentrated to l2J.LL in a Speed Vac 
concentrator (Savant) to achieve a concentration of 200 ng/J.LL. 
Tubes containing 12J.LL of each purified amplimer (200 ng/J.LL), were then wrapped in 
Parafilm™ and posted along with 10 JlL of each primer (diluted to 0.8 pmol/J.LL) to the 
University of Otago for sequencing. 
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Figure 5.1 Purified amp timers on agarose gel for concentration estimation by band intensity. I ~-tL of 
amplimer (8 on left, 10 on right) were loaded alongside 10 ~-tL of molecular weight marker VI. 
5.3 Estimation of DNA concentrations using the scanning spectrophotometer 
5 ~L of purified amplimer isolated using the Agarose Gel DNA Extraction Kit (Boehringer 
Mannheim), were diluted to 500 ~L with water, and the absorbency at 260 nm recorded using a 
double beamed scanning spectrophotometer (Perkin-Elmer). A blank containing 500 ~L of water 
was placed in the reference beam. DNA concentrations were calculated using equation 5.3. 
Equation 5.3 DNA concentration in ~g/mL = A260 x 50 x dilution 
5.3.1 Results and discussion 
70 tubes of PCR product produced 50 ~L of purified amplimer for subjects 8 and 10 using the 
Agarose Gel DNA Extraction Kit (Boehringer Mannheim). The absorbency at 260 nm for 
amplimer 10 was 0.05450, and 0.07515 for amplimer 8. Therefore the concentration of amplimer 
10 was- 270ng/~L, and -370 ng/~L for amplimer 8. An aliquot of each DNA suspension was 
then diluted 100 ng/~L. 
Tubes containing 20 ~L of each purified amplimer (100 ng/~L), were then wrapped in 
Parafilm™ and posted along with 10 ~L of each primer at 3.2 pmol to the University of 
Auckland for sequencing. 
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CHAPTER6 
Sequencing results. 
6.1 Introduction 
Sequencing of amplimers was performed by Tracee Masson-Lawrence of the Centre For Gene 
Research, University of Otago, New Zealand, and by Debbie Reed of the School of Biological 
Sciences, University of Auckland, New.Zealand. Sequencing of amplimers 8 and 10 at the 
University of Otago did not produce any meaningful results. 
Attempts to sequence amplimers 10 and 8 at the University of Otago failed. Sequencing of the 
amplimers at the University of Auckland were successful, and revealed each amplimer to be a 
unique allele for human cathepsin B. The alleles differed due to an extra 19 nucleotides in 
amplimer 10. 
6.2 Sequence failure due to errors in estimation of DNA concentration 
Two attempts to sequence amplimers 8 and 10 at the University of Otago failed. Of the 
sequences received back from this facility, none shared homology with the primers Bocthex8 and 
HucathU (results not shown), no homology with published human cathepsin B gene sequence 
could be found (results not shown), and random 20 bp oligomers selected from within sequence 
for each amplimer did not share homology with any published gene sequences in the NCBI blast 
server (results not shown). 
The Wizard™ PCR Preps purification system (Promega) produced 100 ~L of each amphmer at 
a concentration of 30 ng/~L. Therefore a total of 3000ng of amplimer were purified from the 
contents of70 PCR reaction tubes (section 5.2.1). For amplimer 10, the Agarose Gel DNA 
Extraction Kit (Boehringer Mannheim) produced 50 ~L of amplimer at a concentration of 
270ng/mL, and a total of 13.5 mg of amplimer were purified from the contents of 70 PCR 
reaction tubes (section 5.3.1). The differences in recovery rates of these two kits are not great 
enough to explain the differences between the total amounts of DNA isolated from 70 tubes. The 
estimation of DNA concentration by comparison of band intensities in agarose gels was 
concluded to be grossly underestimated. This meant that template DNA sent to the University of 
Otago was well in excess of 200 ng/~L, and inhibited the sequencing reaction so that no 
meaningful results were produced. 
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6.3 Sequence results from the University of Auckland. 
Template DNA sent to the University of Auckland produced meaningful sequence results, and 
identified the measurement of the absorbency at 260 nm as the most reliable method for 
measuring template DNA concentrations intended for sequencing. 
Amplimers 8 and 10 were sequenced using automated dye terminator reactions. The sequence 
results were good enough to build a consensus sequence for each amplimer (Figure 6.1 ), using 
the aligned upstream and downstream primer sequences for each amplimer (Appendix C.l). 
Amplimer 10 
TGTAATGGTG GCTATCCTGC TGAAGCTTGG AACTTCTGGA CAAGAAAAGG 50 
CCTGGTTTCT GGTGGCCTCT ATGAATCCCA TGTAGgtaag tgtgtcccct 100 
tggccacttt ctggccagat ggattgtttg agcaattaac catcatggct 150 
ttatttgcct ttataaactg ggggttgaga cagaggggct gctgagaggt 200 
gctagccagg tgcacaggcc tctggcagga cctgcctggc gtccatgctg 250 
caggcacgag gcttgccttg ccccaggtct gcctcgccca gctggggctt 300 
ctccgtgggg gctgtaggtt gactccgctt tctcccgggt cccatcagGG 350 
TGCAGACCGT ACTCCATCCC TCCC 374 
Amplimer 8 
TGTAATGGTG GCTATCCTGC TGAAGCTTGG AACTTCTGGA CAAGAAAAGG 50 
CCTGGTTTCT GGTGGCCTCT ATGAATCCCA TGTAGgtaag tgtgtcccct 100 
tggccacttt ctggccagat ggattgtttg agcaattaac catcatggct 150 
ttatttgcct ttataaactg ggggttgaga cagaggggct gctgagaggt 200 
gctagccagg tgcacaggcc tctggcagga cctgcctggc gtccatgctg 250 
caggcacgag gcttgccttg ccccaggtct ********** *********t 281 
ctccgtgggg gctgtaggtt gactccgctt tctcccg.c.gt cccatcagGG 331 
TGCAGACCGT ACTCCATCCC TCCC 355 
Figure 6.1 Consensus Sequences for amplimers 10 and 8. The missing 19 nucleotides in amplim~r 8 
are denoted by "*". g. and&. denote a possible point mutation. Ex on sequence is in upper case, and intron 
sequence is in lower case. 
The first 85 nucleotides in each amplimer share 100% homology with ex on 7 of the published 
human cathepsin B gene sequence (Chan et al., 1986). Amplimer 10 contains an extra 19 
nucleotides in intron 7, which explains its reduced electrophoretic mobility observed in agarose. 
gels (eg. Figure 4.2). Only one cathepsin B gene is thought to exist (Gong et al., 1993), therefore 
these sequencing results identify two unique alleles of this gene. Amplimers 10 and 8 are now 
referred as alleles A and B respectively. 
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CHAPTER 7 
Discussion of sequence results 
7.1 Introduction 
Alleles A and B of the human cathepsin B gene differ by 19 nucleotides in intron 7. It is not 
known if the 19 nucleotides have been inserted into the A allele, or if the 19 nucleotides have 
been deleted from the B allele. The exact position at which the 19 nucleotides are missing from 
the B allele cannot be elucidated. This is because the missing 19 nucleotides contain a CT 
dinucleotide, and the site adjacent to where they are missing from in the B allele contains aCT 
dinucleotide. Figure 7.1 illustrates this. 
B 
B' 
A 
caggcacgag gcttgccttg ccccaggtct 
caggcacgag gcttgccttg ccccaggt** 
caggcacgag gcttgccttg ccccaggtct 
# 
********** *********t 
********** *******ctt 
gcctcgccca gctggggctt 
@ 
Figure 7.1 The A allele is aligned with the corresponding region in the B allele missing the 19 
nucleotides. B' identifies the alternative region missing the 19 nucleotides in the B allele. CT 
nucleotides highlighted with # and @ are discussed in text. 
281 
281 
300 
Therefore in the B allele the 19 nucleotides are either missing to the left of CT -dinucleotide ., 
marked with @ in figure 7.1, or from the right of the CT -dinucleotide marked with a#. The 
following sections discuss the how the 19 nucleotides may alter cathepsin B gene expression, and 
·I 
the implications of being homozygous for either allele. 
7.2 Intron consensus sequences within alleles A and B 
Intron 7 of alleles A and B obeyed the GT-AT rule (Lewin, 1994), as well as the general 
consensus for introns (Figure 7.2), although the 3' 12Py region was not strictly adhered to. Allely 
A contained three G's at positions 337, 338, and 339, and an A at position 344. Allele B 
contained two G's at positions 318 and 320, and an A at position 325. The difference in the 12Py 
regions for the two alleles is discussed in section 7.3. 
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Figure 7.2 General consensus sequence for introns. The bolded intron is separated by "I" from the two 
flanking exons. Subscript numbers indicate the frequencies at which those nucleotides occur (Lewin, 
1994). 
Gene expression generates primary messenger RNA transcripts containing intron sequences 
which cannot be translated. Processing of the primary transcript removes the introns and 
produces secondary mRNA ready for translation. During processing the spliceosome cuts the 5' 
end of the intron to separate the left ex on and the right intron-exon molecule. The 5' end of the 
intron-exon molecule then forms a lariat through the generation of a 5'-2' bond with the A located 
in the branch site. Following lariat formation, cutting at the 3' splicing site releases the free 
intron in lariat form, while the right exon is spliced to the left exon (Lewin, 1994). Failure to 
process transcripts properly can result in the skipping of exons. The probable branch sites for 
alleles A and B were located, and aligned with the branch site consensus sequence in Table 7 .1. 
Table 7.1 Probable branch sites for the A and B alleles. The G at positions 317 and 298 for each allele 
does not strictly conform to the consensus (Lewin, 1995). 
Consensus Se u 
A allele 
B allele T 
7.3 Implications of the extra 19 base pairs in allele A 
The Oligo™ program was used to identify a stable loop structure (Figure 7.3) which 
incorporates the extra 19 nucleotides in the A allele. Free energy change for the loop structure 
was -10.1 kcal moJ-1. There was also a stable loop structure formed in the similar region of allele 
B (Figure 7.4). The free energy change for this loop is -6.8 kcal mol-l. 
c 
c 
G 
T 
c 
T 
G 
T 
G 
G:C 
A:T 
C:G 
C:G 
C:G 
C:G 
G:C 
c 
G 
c 
c 
c 
A 
5'G260N(x)-CTT TTCTCCGN(x)-G337 3• 
Figure 7.3 The stable loop structure afforded by 19 extra nucleotides (bolded) in allele A. The 
flanking regions started with Gat position 260 and ended with the Gat position 337. 
T 
c 
T 
G 
G 
T 
A G 
C:G 
C:G 
C:G 
C:G 
G:C 
c 
T 
T 
c 
G 
5'-G250 -N(x)CTT TGTN(x)-G320 -3• 
Figure 7.4 The stable loop structure formed in absence of the 19 extra nucleotides in allele B. The 
flanking regions started with Gat position 250 and· ended with the Gat position 320. The 19 extra .• 
nucleotides lied within this region of the A allele. 
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In the absence of the extra 19 nucleotides, a loop with decreased free energy change in 
nucleotides 250-320 may form in the primary transcript for allele B. This may confer less 
stability upon the primary transcript, making it more susceptible to digestion by nucleases. If this 
occurred in vivo then it is possible that the A allele produces primary transcripts with a greater 
half life than transcripts for the B allele. Therefore individuals homozygous for the A allele 
(A/A) may display altered cathepsin B gene expression through increased levels of mRNA and 
protein. Conversely an individual homozygous for the B allele (BIB) may display decreased 
levels for cathepsin B mRNA and protein. Levels of mRNA and protein for cathepsin B in 
heterozygotes (AlB) may be intermediate. While one allele in an AlB individual may produce a 
more stable transcript, this may be offset by concomitant destruction of the less stable transcript. 
Alternative branch sites within introns can be used in lariat formation, and in some cases 
generate altered mRNAs deficient in one or more exons. The extra 19 nucleotides in allele A 
contained a region which could potentially be used as an alternative branch site (Table 7 .2), 
although it did not strictly conform to the branch site consensus sequence. 
Table 7.2 The possible alternative branch site in allele A. The C and G nucleotides flanking the A do 
not conform to the consensus for the branch site. 
Consensus Sequence Py80 N Py80 Py87 Pu75 A Py95 
A allele C285 G c c c A G 
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Inspection of the downstream sequence indicates that this alternative branch site is not likely to 
be used. The first alternative down stream splice site (A316G) does not conform to the splice site 
consensus sequence (Figure7.1), and would destroy the reading frame by adding 31.nucleotides 
of intron to the 5' end of ex on 7. 
If the extra 19 nucleotides in allele A have been inserted from another region of the human 
genome, then their origins are obscure. The 19 nucleotide insert was sent to the NCBI blast 
server with the CT dinucleotide at either end, but no homology was found with any published 
gene sequence (search results in appendix C.3). 
Current literature detailing mutations in introns, describe those which have detrimental effects 
on the processing of primary transcripts, to the extent that mutated and prematurely terminated 
proteins are expressed. Longo et al., (1995) identified one such mutation in a patient suffering 
from leprechaunism. Using PCR technology t~ey characterised a G¢ A transition in the first 
nucleotide in intron 13 of the insulin receptor gene. This point mutation activated a cryptic 1 
splice site 27 bp upstream in exon 13, and caused an in-frame deletion of the amino acids 859-
867 in the extracellular domain of the B subunit insulin receptor. Sun et al., (1995) describe a 
similar transition in the 3rd intron for the human low density lipoprotein-receptor gene. This 
G¢A transition results in mRNA lacking exon 3, which codes for the 41 amino acids found in 
the ligand binding domain of the low density lipoprotein-receptor. 
Literature detailing silent mutations within gene intron sequences are scarce, simply because 
there is more impetus behind identifying and characterising the underlying mutations in genetic 
disorders that seriously affect health. 
7.4 Identification of a possible nucleotide substitution 
A nucleotide substitution was identified. Sequencing from the upstream (HucathU) primer 
revealed a Gat position 338 in allele A, and a Cat position 319 in allele B. Table 7.3 below 
illustrates this. 
Table 7.3 Possible point mutation between alleles A and B. 
Allele * 
A T 333 c c c G G G T c c c A 
B T 314 c c c G c G T c c c A 
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Consultation of the signal strengths (Appendix C.2) for these regions supported the existence of 
the substitution. Figure 7.5 illustrates that in the A allele there were signals for both G and C at 
position 338, with G being the stronger signal. In allele B there was a lone signal for Cat 
position 319. The absence of a weak underlying G (or any other) signal at position 319 suggests 
that C is the valid nucleotide at this position in the B allele . 
c~ c~ c~ G G G r c::; c; c; fl, T c ; C 1 CCC G c: G r (; C C A f C 
Figure 7.5 Signal strengths for the regions containing possible nucleotide substitution. Allele A is on. 
the left, and allele B is on the right. Position numbers are from signal strengths and should be ignored. 
Because these nucleotides reside in the 12 pyrimidine tract of intron 7, the substitution has 
probably been a C¢G substitution at position 338 in allele A. It is less likely to have been a 
G¢C substitution at position 319 in the B allele, as the 12 pyrimidine region is an area generally 
conserved to pyrimidines only. 
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It is not known if this substitution is unique to subject 7, or common in all B alleles carried by 
subjects 1, 2, 3, 4, 5, 6, 7, 8, and 9. Sequencing of the B allele from other homozygous 
individuals would address this issue. This nucleotide substitution is not be expected to alter 
processing of the primary mRNA transcript in any way. It serves only to increase the number of 
purines in the 12 pyrimidine tract in the A allele. 
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CHAPTERS 
Conclusions 
8.1 Conclusions 
This study has led to the characterisation of two previously unreported alleles of the human 
cathepsin B gene. Alleles A and B differ through an extra 19 nucleotides in intron 7 of the A 
allele. The extra 19 nucleotides in allele A are not thought to affect the processing of primary 
mRNA transcripts, but can potentially increase the half-life of the transcript. Homozygosity for 
either allele may lead to altered cathepsin B gene expression, and may result in different 
cathepsin B to cysteine protease inhibitor ratios in cells. An alteration in this ratio could then 
enhance tumour development and progression, conditions where cathepsin B gene a,ctivity is 
commonly upregulated. 
Alleles A and B also have potential to be used as polymorphic markers in gene linkage analyses 
of human chromosome 8. 
8.2 Future research in this area 
The A and B alleles are expected to be lodged in the GENBANK database in late November of 
1995. Primers HucathU and Bocthex8 will be used to screen family groups to determine if the 
alleles are inherited according to Mendelian segregation, and also to observe the frequencies of 
inheritance for each allele. This work is expected to be undertaken by myself at the John Cortin 
School of Medical Research in Canberra, Australia, over the summer of 1995-96. Following 
that, studies on the levels of cathepsin B gene expression in AI A and BIB individuals would be 
pertinent. It is possible that the presence of primary transcripts for cathepsin B with increased 
half-lives in transformed cells may promote tumour invasion and progression. Therefore 
research in this area would be valuable if any associations between tumour development and 
homozygosity for the A allele are to be found. 
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Appendix A.l 
Primer homology results from the NCBI blast server 
Query= HucathU 
(25 letters) 
Database: Non-redundant PDB+GBupdate+GenBank+EMBLupdate+EMBL 
575,107 sequences; 395,388,600 total letters. 
Sequences producing high-scoring segment pairs: 
gbiT723141T72314 yc68g10.rl Homo sapiens eDNA clone 858 .. . 
gbiR521991R52199 yg85e07.rl Homo sapiens eDNA clone 402 .. . 
gbiM132301HUMCTHB Human lysosomal proteinase cathepsin B ... 
gbiL165101HUMCATHB Homo sapiens cathepsin B mRNA, complet .. . 
gbiM142211HUMCTSB Human cathepsin B proteinase mRNA, com .. . 
Homology 
>gbiT723141T72314 yc68g10.rl Homo sapiens eDNA clone 85890 5' similar to 
gb:Ml4221 CATHEPSIN B PRECURSOR (HUMAN);. 
Length= 282 
Score= 125 (34.5 bits), Expect= 0.0084, P = 0.0083 
Identities= 25/25 (100%), Positives= 25125 (100%), Strand= Plus I Plus 
Query: 1 TGTAATGGTGGCTATCCTGCTGAAG 25 
1111111111111111111111111 
Sbjct: 118 TGTAATGGTGGCTATCCTGCTGAAG 142 
>gbiR521991R52199 yg85e07.rl Homo sapiens eDNA clone 40205 5' similar to 
gb:M14221 CATHEPSIN B PRECURSOR (HUMAN);. 
Length 386 
Score= 125 (34.5 bits), Expect= 0.0091, P = 0.0090 
Identities= 25/25 (100%), Positives= 25125 (100%), Strand= Plus I Plus 
Query: 1 TGTAATGGTGGCTATCCTGCTGAAG 25 
Sbjct: 1111111111111111111111111 149 TGTAATGGTGGCTATCCTGCTGAAG 173 
>gbiM132301HUMCTHB Human lysosomal proteinase cathepsin B rnRNA, 3' end. 
Length= 630 
Score= 125 (34.5 bits), Expect= 0.0098, P = 0.0098 
Identities= 25125 (100%), Positives= 25/25 (100%), Strand= Plus I Plus 
Query: 1 TGTAATGGTGGCTATCCTGCTGAAG 25 
Sbjct: 1111111111111111111111111 58 TGTAATGGTGGCTATCCTGCTGAAG 82 
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Appendix A.l 
Primer homology results from the NCBI blast server 
Query = Hucath U 
(25 letters) 
Homology (continued) 
>gbiL165101HUMCATHB Homo sapiens cathepsin B mRNA, complete cds. 
Length = 1996 
Score= 125 (34.5 bits), Expect= 0.011, P = 0.011 
Identities = 25/25 ( 100% ), Positives = 25125 ( 100% ), Strand = Plus I Plus 
Query: 1 TGTAATGGTGGCTATCCTGCTGAAG 25 
1111111111111111111111111 
Sbjct: 625 TGTAATGGTGGCTATCCTGCTGAAG 649 
>gbiM142211HUMCTSB Human cathepsin B proteinase mRNA, complete cds. 
Length = 2002 
Score= 125 (34.5 bits), Expect= 0.011, P = 0.011 
Identities= 25125 (100%), Positives= 25125 (100%), Strand= Plus I Plus 
Query: 1 TGTAATGGTGGCTATCCTGCTGAAG 25 
1111111111111111111111111 
Sbjct: 642 TGTAATGGTGGCTATCCTGCTGAAG 666 
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Appendix A.l 
Primer homology results from the NCBI blast server 
Query = BOCTHEX8 
(24 letters) 
Database: Non-redundant PDB+GBupdate+GenBank+EMBLupdate+EMBL 
575,107 sequences; 395,388,600. total letters. 
Sequences producing high-scoring segment pairs: 
gbiM132301HUMCTHB Human lysosomal proteinase cathepsin B .. . 
gbiL060751BOVCATHB Bos taurus cathepsin B mRNA, complete .. . 
gbiL165101HUMCATHB Homo sapiens cathepsin B mRNA, complet... 
gbiM142211HUMCTSB Human cathepsin B proteinase mRNA, com ... 
gbiT723141T72314 yc68g10.rl Homo sapiens eDNA clone 858 ... 
Homology 
>gbiM132301HUMCTHB Human lysosomal proteinase cathepsin B mRNA, 3' end. 
Length= 630 
Score= 120 (33.2 bits), Expect= 0.017, P = 0.017 
Identities= 24124 (100%), Positives= 24/24 (100%), Strand= Minus I Plus 
Query: 24 TGCAGACCGTACTCCATCCCTCCC 1 
111111111111111111111111 
Sbjct: 145 TGCAGACCGTACTCCATCCCTCCC 168 
>gbiL060751BOVCATHB Bos taurus cathepsin B mRNA, complete cds. 
Length= 1973 · 
Score= 120 (33.2 bits), Expect= 0.019, P = 0.019 
Identities= 24124 (100%), Positives= 24124 (100%), Strand= Minus I Plus 
Query: 24 TGCAGACCGTACTCCATCCCTCCC 1 
111111111111111111111111 
Sbjct: 535 TGCAGACCGTACTCCATCCCTCCC 558 
>gbiL165101HUMCATHB Homo sapiens cathepsin B mRNA, complete cds. 
Length = 1996 
Score= 120 (33.2 bits), Expect= 0.019, P = 0.019 
Identities = 24124 ( 100% ), Positives = 24124 ( 100% ), Strand = Minus I Plus 
Query: 24 TGCAGACCGTACTCCATCCCTCCC 1 
111111111111111111111111 
Sbjct: 712 TGCAGACCGTACTCCATCCCTCCC 735 
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Appendix A.l 
Primer homology results from the NCBI blast server 
Query = Bocthex8 
(25 letters) 
Homology (continued) 
>gbiM142211HUMCTSB Human cathepsin B proteinase mRNA, complete cds. 
Length = 2002 
Score= 120 (33.2 bits), Expect= 0.019, P = 0.019 
Identities= 24/24 (100%), Positives= 24/24 (100%), Strand= Minus I Plus 
24 TGCAGACCGTACTCCATCCCTCCC 1 
I I I I I I II II II I I I I II I I I II I 
Query: 
Sbjct: 729 TGCAGACCGTACTCCATCCCTCCC 752 
>gbiT723141T72314 yc68g10.rl Homo sapiens eDNA clone 85890 5' similar to 
gb:M14221 CATHEPSIN B PRECURSOR (HUMAN);. 
Length= 282 
Score= 113 (31.2 bits), Expect = 0.058, P = 0.056 
Identities 23/24 (95%), Positives= 23124 (95%), Strand= Minus I Plus 
Query: 24 TGCAGACCGTACTCCATCCCTCCC 1 
I 1111111111111111111111 
Sbjct: 205 TNCAGACCGTACTCCATCCCTCCC 228 
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Appendix A.2 
Visualisation of DNA by gel electrophoresis 
Materials: 
Water 
Water mentioned in text is autoclaved reverse osmosis water. 
TAE Stock x 10: 
Tris 
Glacial acetic acid 
EDTA (0.5M) 
TBE Stock x 10: 
TRIS 
Borate 
EDTA (Na) 
water 
48.4 g 
11.4 mL 
20.0mL 
make to 1L, pH = 8 
108.0 g 
55.0 g 
9.3 g 
make to 1 L 
1 x TBE or TAE buffer: 
Dilute stock 10 x with ddH20. 
Add 5JlL ethidium bromide (lOmg/ml). 
Load buffer: 
4MUrea 
50%Sucrose 
0.1 %Bromophenol Blue 
0.1 %Xylenocyanol 
0.25M EDTA 
4.8 g 
10.0 g 
2.0 mL 
. 2.0mL 
M_g 
water make to 20.0 ml 
Molecular weight markers 
100 base pair ladder (GIBCO BRL) 
[stock] = 1.0 Jlg/JlL 
dilute 10 JlL stock and 20 JlL load buffer with 170 JlL H2o. 
(0.5% stock) 
(0.5% stock) 
DNA Molecular weight marker VI (Boehringer Mannheim). 
[stock] = 0.25Jlg/JlL 
dilute 10JlL stock and 20JlL load buffer with 170JlL H20. 
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Appendix A.2 
Preparation of a 2% agarose gel. 
Method 
0.6g Agarose (SeaKem) mixed with 30.0 ml 1 x TBE. 
Record weight, heat to dissolve agarose completely (microwave for 2 x 30 seconds on high). 
Allow to cool. Adjust weight back to original with H20. 
Pour into prepared gel mould. Allow to set. 
Set up tank with gel and 1 x TBE buffer. 
Prepare samples by mixing 2 J.lL load buffer+ 18 JlL sample (Or to same proportions). 
Load all20 JlL (or 5 JlL), and load 5 J!L molecular weight marker in an adjacent well. 
Electrophorese at 90V for 50 minutes.Visualise bands using UV Transilluminator and 
photograph results, or continue electrophoreses if needed. 
Preparation of a 2% TAE agarose gel. 
The same as above, except 1 x TBE is substituted with 1 x T AE buffer. 
45 
Appendix B.l 
CONSENT TO PARTICIPATE IN A LABORATORY 
EXPERIMENT. 
46 
give my consent to participate in a laboratory 
experiment as part of a study for the subject BICH 460 at Lincoln University. 
This experiment will consist of the withdrawal of 10 mL of my blood by venipuncture (a sterile 
disposable needle inserted into my vein) carried out by a qualified medical technologist, 
registered nurse or medical practitioner. The blood will be used for DNA extraction, and gene 
analysis. 
The possible risks of this procedure have been fully explained to me. I understand these risks to 
include the small but finite possibility of subdermal haematoma (bleeding under the skin), 
infection from bacterial, viral, or other agents, complications of haemophilia (uncontrolled 
bleeding), and moderate but transient pain, distress, or discomfort. · 
I understand that the giving of this blood sample will be of no direct benefit to me. I understand 
that.in the event of medical complications arising as a result of this experiment, Lincoln 
University provides the facilities of the student health service to assist me. I undertake to notify 
Lincoln University immediately of any complications resulting from my participation. 
I further understand that I have the right to refuse to participate in this experiment, and that if I 
do refuse no adverse reaction or effect on my marks, or my standing as either a student or staff 
member will result. I acknowledge that I have been granted sufficient time to consult with my 
family, or legal guardian, medical or otherwise advisors before signing this consent. 
Having consideration to all of the foregoing I do hereby freely and voluntarily give my consent. 
Signed: Signed: 
Name: Name: J. R. MacKenzie 
Date: Date: 
Appendix B.2 
Hi-salt DNA extraction reagents. 
Red and white blood cell lysing solution. 
0.17 M Ammonium chloride (NH4CL). 
Wash buffer. 
10 mM Sodium Chloride (NaCl) lOmM EDTA, pH= 8. 
Solubilisation solution. 
50 mM Sodium Hydroxide (NaOH). 
Neutralisation buffer. 
1M Tris-HCL, pH= 8. 
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Appendix C.l 
Homology between A and B alleles 
Comparison of 
with 
with 
with 
10 DOWNC 
10 UP 
8 UP 
8 DOWNC 
HucathU 
Exon 7 
10 DOWNC 
10 UP 
8 UP 
8 DOWNC 
Exon 7 
10 DOWNC 
10 UP 
8 UP 
8 DOWNC 
Intron 7 
10 DOWNC 
10 UP 
8 UP 
8 DOWNC 
TGTAATGGTGGCTATCCTGCTGAAG 
CTGTAATGGTGGCTATCCTGCTGAAGCTTGGAACTTCTGGACAAGAAAAGGCCTGGTTTCTGGTGGCCTC 
-TGTAATGGTGGCTATCCTGCTGAAGCTTGGAACTTCTGGACAAGAAAAGGCCTGGTTTCTGGTGGCCTC 
-------------------GGGAA--ACG---------GGACANGAAAAGGG-TGGTTGCTGGTGGCCTC 
-------------------TTCGNACACGGGGCCTTCTGGACAAGAAAAGGGCTGGTTTCTGGTGGCCTC 
-TGTAATGGTGGCTATCCTGCTGAAGCTTGGAACTTCTGGACAAGAAAAGGCCTGGTTTCTGGTGGCCTC 
TATGAATCCCATGTAGgtaag-------------------Intron7-----------------------
TATGAATCCCATGTAGGTAAGTGTGTCCCCTTGGCCACTTTCTGGCCAGATGGATTGTTTGAGCAATTAA 
TATGAATCCCATGTAGGTAAGTGTGTCCCCTTGGCCACTTTCTGGCCAGATGGATTGTTTGAGCAATTAA 
TATGAATCCCATGTAGGTAAGTGTGTCCCCTTGGCCACTTTCTGGCCAGATGGATTGTTTGAGCAATTAA 
TATGAATCCCATGTAGGTAAGTGTGTCCCCTTGGCCACTTTCTGGCCAGATGGATTGTTTGAGCAATTAA 
CCATCATGGCTTTATTTGCCTTTATAAACTGGGGGTTGAGACAGAGGGGCTGCTGAGAGGTGCTAGCCAG 
CCATCATGGCTTTATTTGCCTTTATAAACTGGGGGTTGAGACAGAGGGGCTGCTGAGAGGTGCTAGCCAG 
CCATCATGGCTTTATTTGCCTTTATAAACTGGGGGTTGAGACAGAGGGGCTGCTGAGAGGTGCTAGCCAG 
CCATCATGGCTTTATTTNCCTTTATAAACTGGGGGTTGAGACAGAGGGGCTGCTGAGAGGTGCTAGCCAG 
Intron 7 ----------------------------------------------------------------------
10DOWNC GTGCACAGGCCTCTGGCAGGACCTGCCTGGCGTCCATGCTGCAGGCACGAGGCTTGCCTTGCCCCAGGTC 
10 UP GTGTACAGGACTCTGGCAGGACCTGTCTGGCGTCCATGCTGCAGGNACGAGGCTTGCCTNGCCCCAGGTC 
8 UP GTGCACAGGCCTCTGGCAGGACCTGCCTGGCGTCCATGCTGCAGGCACGAGGCTTGCCTNGCCCCAGGTC 
8 DOWNC GTGCACAGGCCTCTGGCAGGACCTGCCTGGCGTCCATGCTGCAGGCACGAGGCTTGCCTTGCCCCAGGTC 
Intron 7 
10 DOWNC 
10 UP 
8 UP 
8 DOWNC 
-Bocthex8 
Exon 8 
10 DOWNC 
10 UP 
8 UP 
8 DOWNC 
TCCCTCGCCCAACTGGGGCTTNCTCCGTGGGGNCTGTANGT-GACCCCGCTNTCTG--CGCCAGTGCTCA 
TGCCTCGCCCAGNTGGGGCTT-CTCCGTGGGGGCTGTAGGTTGACTCCGCTTTCTC-CCGGGTCCCATCA 
T--------------------TCTCCGNGGGGGGTGTAGGTTGACTCCGCTTTCTC-CCGCGTCCCATCA 
T-------------------TNCTCCGTGGGGGCTGTAGGNTGACCCCGCTTTCCTNCCGCANTCGCCCG 
@@@@@@@@@@@@@@@@@@@A% A %A * 
$ $A 
TGCAGACCGTACTCCATCCCT-CCC 
GGGTGCAGACCGTACTCCATCCCT-CCC 
A---------------------------
GGGTGCAGACCGTACTCCANCCCT-CNC 
GGGTGCAGACCGTACTCCATCCCTACCC 
GGNCCTAA--------------------
% 
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Key •w• identifies 1 nucleotide which differs from three others at that position. The corresspond-
ing nucleotide in the consensus sequence is based on the agreement between the 3 similar 
nucleotides. Published nucleotides (Exon 7 and Exon 8) were also used where appropriate. 
11 @ 11 identifies each of the 19 nucleotide insertion in allele A 
11$11 identifies nucleotides which needed to be resolved from the signal strengths 
11
*
11 identifies other possible polymorphism between alleles A and B. 
11 % 11 identifies nucleotides thought to be inserted by the gel reader, and which were not 
included in the consensus sequence. 
Amplimer from subject 10 represents Allele A 
Amplimer from subject 8 represents Allele B 
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Version 2.1.1 
9 up.1 
Jason MacKenzie 
Lane 32 
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DT6%Ac{A Set-AnyPrimer} 
#9008209matrixA 
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Page 1 of 1 
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Tue, 31 Oct 1995 5:19PM 
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Version 2.1.1 
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11 down.1 
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DT6%Ac{A Set-AnyPrimer} 
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Page 1 of 1 
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Spacing : 11 .1 0 SemiAdaptive 
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Appendix C.3 
19 nucleotide sequence search results 
Query = insertct 
> gcctcgcccagctggggct 
( 19 letters) 
Database: Non-redundant PDB+GBupdate+GenBank+EMBLupdate+EMBL 
575,107 sequences; 395,388,600 total letters. 
Sequences producing High-scoring Segment Pairs: Score P(N) N 
***NONE*** 
Query = ctinsert 
> ctgcctcgcccagctgggg 
( 19 letters) 
Database: Non-redundant PDB+GBupdate+GenBank+EMBLupdate+EMBL 
575,107 sequences; 395,388,600 total letters. 
Sequences producing High-scoring Segment Pairs: Score P(N) N 
***NONE*** 
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